Skip to main content
Terry D. Box

Terry D. Box, MD

Languages spoken: English

Clinical Locations

University Hospital

Liver Transplant
801-213-9797
  • Terry Box, MD, is an Associate Professor in the Department of Internal Medicine at the University of Utah School of Medicine. He is also a Huntsman Cancer Institute (HCI) investigator and a member of HCI's Gastrointestinal Cancer Program. Dr. Box is certified by the American Board of Internal Medicine and the National Board of Medical Examiners.

    Dr. Box's expertise is in diagnosing and treating diseases of the liver. He has specific expertise in hepatitis B and C, hepatocellular carcinoma, and liver transplantation. Dr. Box completed his medical degree at the University of Texas Southwestern Medical School, followed by residency and fellowship at the University of Utah.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Gastroenterology)
    National Board of Medical Examiners
  • Terry Box, MD, is an Associate Professor in the Department of Internal Medicine at the University of Utah School of Medicine. He is also a Huntsman Cancer Institute (HCI) investigator and a member of HCI's Gastrointestinal Cancer Program. Dr. Box is certified by the American Board of Internal Medicine and the National Board of Medical Examiners.

    Dr. Box's expertise is in diagnosing and treating diseases of the liver. He has specific expertise in hepatitis B and C, hepatocellular carcinoma, and liver transplantation. Dr. Box completed his medical degree at the University of Texas Southwestern Medical School, followed by residency and fellowship at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Gastroenterology)
    National Board of Medical Examiners

    Education history

    Other Training Clinical Transplant Hepatology - California Pacific Medical Center
    Gastroenterology, Clinical Nutrition and Hepatology - University of Utah Affiliated Hospitals Fellow
    Chief Resident Internal Medicine - University of Utah School of Medicine Chief Resident
    Internal Medicine - University of Utah School of Medicine Resident
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Medicine - University of Texas Southwestern M.D.
    Undergraduate Mathematics - University of Texas, Austin B.A.

    Selected Publications

    Journal Article

    1. Cave, Barbra, Serper, Marina, Box, Terry, Ramers, Christian, Stainbrook, Tuesdae, Reau, NancyTrooskin, Stacey, Sulkowski, Mark, Dieterich, Douglas, Dinani, Amreen (2022). A simplified algorithm for managing hepatitis C infection by leveraging telemedicine. Gastroenterology & Hepatology, 13(1), 12-20.
    2. Box TD, Utech KA (February 2019). Unique Empathy Gained: Liver Transplant Specialist as a Liver Transplant Patient. Tex Heart Inst J, 46(1), 65-66.
    3. Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS (2016). Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. Antimicrob Agents Chemother, 60(10), 6207-15.
    4. Lawitz EJ, ORiordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J (2015). Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrob Agents Chemother, 60(3), 1546-55.
    5. Boynton K, Flynn A, Box T, Dalpiaz A, Willis L, Kay T, Valentine JF (06/01/15). Inflammatory bowel disease education: I can hear the extension for community healthcare outcomes. Inflamm Bowel Dis, 21(6), 1407-8.
    6. Thornton K, Deming P, Manch R, Moore A, Gish R, Sussman N, Khaderi S, Scott J, Mera J, Box T, Qualls C, Sedillo M, Arora S (04/15/2015). Response guided therapy is not dead: Low Sustained Virologic Response (SVR) rates in patients who have detectable Hepatitis C Virus (HCV) at week 4 of treatment with SOFOSBUVIR (SOF) containing regimens. J Hepatol, 62(Supp 2), S290.
    7. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR (2014). ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med, 370(21), 1983-92.
    8. Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW (2014). Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model--Arizona and Utah, 2012-2014. MMWR Morb Mortal Wkly Rep, 63(18), 393-8.
    9. Harrison JD, Selzman CH, Thiesset HF, Box T, Hutson WR, Lu JK, Campsen J, Sorensen JB, Kim RD (2014). Minimally invasive aortic valve replacement with orthotopic liver transplantation: report of a case. Surg Today, 44(3), 546-9.
    10. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Najera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES (2013). Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Gastroenterology, 145(4), 790-800.e3.
    11. Lalezari J, Box T, ORiordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai J, Mayers D (2013). IDX184 in combination with pegylated interferon-alpha2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. Antivir Ther, 18(6), 755-64.
    12. Remien CH, Adler FR, Waddoups L, Box TD, Sussman NL (2012). Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death. Hepatology, 56(2), 727-34.
    13. Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T (2012). Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl, 18(4), 423-33.
    14. Sulkowski M, Vierling J, Brown K, Flamm B, Kwo P, Mullen K, Box T, et al (2008). Probability of Sustained Virologic Response is Associated with the magnitude of HCV RNA Reduction at Week 4 of Treatment with Peg-Interferon plus Ribavirin; Results of the IDEAL Trial. Hepatology, 48(4 Suppl), 1144A.
    15. Gaglio PJ, Rodriguez-Torres M, Herring R, Anand B, Box T, Rabinovitz M, Brown RS (2004). Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol, 38(7), 599-604.
    16. Ahmed F, Jacobson IM, Brown RS, Vierling J, Box T, Cochran JL, et al (2004). Arrhythmias During Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C: Observations from the WIN-R Trial. Gastroenterology, 126(4 Suppl 2), M1226.
    17. Korman LY, Overholt BF, Box T, Winker CK (2003). Perforation during colonoscopy in endoscopic ambulatory surgical centers. Gastrointest Endosc, 58(4), 554-7.
    18. Burgert SJ, Burke JP, Box TD (1995). Reversible nitrofurantoin-induced chronic active hepatitis and hepatic cirrhosis in a patient awaiting liver transplantation. Transplantation, 59(3), 448-9.
    19. Box TD, Keefe EB, Esquivel CO (1993). Liver Transplantation in Elderly Patients. Pract Gastroenterol, 17, 22-27.

    Review

    1. AlRabadi L, Box T, Singhania G, AlMarji C, Agarwal A, Hall I, Gordon CE, Tran H (2018). Rationale for treatment of hepatitis C virus infection in end‐stage renal disease patients who are not kidney transplant candidates. [Review]. Hemodial Int, 22(S1), S45- S52.

    Case Report

    1. Salek J, Byrne J, Box T, Longo N, Sussman N (2010). Recurrent liver failure in a 25-year-old female. Liver Transpl, 16(9), 1049-53.

    Editorial

    1. Box, Terry (2022). Donor Livers Must Go to Our Sickest Patients.

    Abstract

    1. Thornton K, Price J, Deming P, MSedillo M, Scott J, Aronsohn A, Box T, Sussman N, Khaderi S, Gish R, Page K, Arora S (October 2017). Expanding HCV Treatment Access: Training Primary Care Providers in the U.S. using the ECHO Model [Abstract]. Hepatology, 66(No. 1 (Suppl.)), 607A.
    2. Mera J, Joshi K, Thornton K, Box T, et al (2016). High Rates of Sustained Virologic Response among HCV Infected Native Americans Treated with Direct Acting Anti-Virals. [Abstract]. Hepatology, 64(1 (Suppl)), 450A.
    3. F Georgie, S Nafisi, A Kohli, K Thornton, J Reynolds, A Moore, R Gish, J Scott, P Deming, M Sedillo, C Qualls, T Box, P Cox, J Mera, A Miller, N Sussman, S Khaderi, R Manch, S Arora (2016). Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo ModelJournal of Hepatology , Volume 64 , Issue 2 , S818 - S819 [Abstract]. Journal of Hepatology, 64(2), S818-S819.
    4. Eric Lawitz, Fred Poordad, Juan Rondon, Terry D Box, Stefan Zeuzem, Peter Buggisch, Kelly A Wong, Christopher T Jones, Carmen Ayala, Baldur Magnusson, Christopher M Owens, Lijuan Jiang, Kai Lin, Kimberley Caliri, Kenneth Tack, Richard Colvin, Yat Sun Or (12/01/2015). EDP-239, a novel HCV NS5A inhibitor, demonstrates potent antiviral activity after a single dose treatment of genotype 1 HCV patients [Abstract]. Hepatology, 62(1 (Suppl)), 1306A.
    5. Fred Poordad, Michael Bennett, Thomas E Sepe, Eric Cohen, Robert Reindollar, Gregory T Everson, Raymond W Phillips, Asma Siddique, Greg Sullivan, Terry D Box, Bo Fu, Tami Pilot-Matias, Manal Abunimeh, Daniel E Cohen, Ziad Younes (12/01/15). Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and SofosbuvirFred Poordad, Michael Bennett, Thomas E. Sepe, Eric Cohen, Robert Reindollar, Gregory T. Everson, Raymond W. Phillips, Asma Siddique, Greg Sullivan, Terry D. Box, Bo Fu, Tami Pilot-Matias, Manal Abunimeh, Daniel E. Cohen, Ziad YounesHEPATOLOGY, VOLUME 62, NUMBER 6 (SUPPL), page 1392A [Abstract]. Hepatology, 62(6 (Suppl)), 1392A.

    Newspaper

    1. Box T (May 2016). Op-ed: ECHO Act helps bring cutting-edge medicine to rural patients. Salt Lake Tribune.

    Video/Film/CD/Web/Podcast

    1. Box T, Pearlman B, Speigle M (2018). Hepatitis C Update: A Growing Challenge With Evolving Management SolutionsSource: Hepatitis C: Simplified Management From Screening to CureIn this updated CME-certified interactive presentation targeted to primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment. [Web]. Clinical Care Options. Available: Released: 1/17/2018 [Web]. Clinical Care Options. Available: https://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20Primary/Interactive%20Virtual%20Presentation/HCV_Primary.aspx#.
    2. Box T (2017). Hepatitis C Update for Primary CareIn this CME-certified interactive presentation tailored for primary care clinicians, Terry D. Box, MD, reviews age-based and risk-based HCV screening, optimal treatment and counseling strategies for HCV-infected patients, and the parameters that warrant referral to specialist care.Source: Hepatitis C Update: A Growing Challenge With Evolving Management SolutionsFaculty: Terry D. Box MDReleased: 2/21/2017 [Web]. Clinical Care Options. Available: https://www.clinicaloptions.com/Hepatitis.aspx.
  • News & Podcasts